Back to search
FDAFDA · Food and drugs·Recall number D-0040-2024

Epinephrine-Lidocaine HCl (0.25mg/mL and 7.5mg/mL) 1mL Single Use Intraocular injection Preservative Free NDC 71384-640-01 Not for resale. Office use only. Lot: 23APR018 Date Compounded: 24APR2023 Expires on: 17APR2024. In case of adverse event contact: www.fda.gov/medwatch or (800)-FDA-1088 Imprimis NJOF, LLC. 1705 Route 46 West, Unit 6B, Ledgewood, NJ, 07852 (844) 446-6979

Published October 11, 2023 · Recall initiated: October 3, 2023

Summary

FDA records drug Class III recall D-0040-2024, published October 11, 2023 and initiated October 3, 2023. Recalling firm: Imprimis NJOF, LLC; Status: Terminated; Reported quantity: 364 bags (1 mL filled in 2 mL glass amber vials; 20 vials shipped in a bag); Lot: 23APR018. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Subpotent: Failing Test Results for Epinephrine

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Imprimis NJOF, LLC
Distributor
Nationwide
Lot
23APR018
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Epinephrine-Lidocaine HCl (0.25mg/mL and 7.5mg/mL) 1mL Single Use Intraocular injection Preservative Free NDC 71384-640-01 Not for resale. Office use only. Lot: 23APR018 Date Compounded: 24APR2023 Expires on: 17APR2024. In case of adverse event contact: www.fda.gov/medwatch or (800)-FDA-1088 Imprimis NJOF, LLC. 1705 Route 46 West, Unit 6B, Ledgewood, NJ, 07852 (844) 446-6979 recalled?

Yes. FDA published recall D-0040-2024 on October 11, 2023. Reported hazard: Subpotent: Failing Test Results for Epinephrine

What should I do if I have this product?

Voluntary: Firm initiated · Letter